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Abstract
Background: Prostate cancer is one of the most frequent malignancies in males. Nevertheless, to
this moment, there is no specific routine diagnostic marker to be used in clinical practice. Recently,
the identification of a membrane testosterone binding site involved in the remodeling of actin
cytoskeleton structures and PSA secretion, on LNCaP human prostate cancer cells has been
reported. We have investigated whether this membrane testosterone binding component could be
of value for the identification of prostate cancer.
Methods: Using a non-internalizable testosterone-BSA-FITC analog, proven to bind on membrane
sites only in LNCaP cells, we have investigated the expression of membrane testosterone binding
sites in a series of prostate carcinomas (n = 14), morphologically normal epithelia, taken from areas
of the surgical specimens far from the location of the carcinomas (n = 8) and benign prostate
hyperplasia epithelia (n = 10). Isolated epithelial cells were studied by flow cytometry, and touching
preparations, after 10-min incubation. In addition, routine histological slides were assayed by
confocal laser microscopy.
Results: We show that membrane testosterone binding sites are preferentially expressed in
prostate carcinoma cells, while BPH and non-malignant epithelial cells show a low or absent binding.
Conclusions: Our results indicate that membrane testosterone receptors might be of use for the
rapid routine identification of prostate cancer, representing a new diagnostic marker of the disease.
Background
Androgens are classically acting in androgen-receptor pos-
itive tissues, like the human prostate, as selective tran-
scription factors, after binding to specific intracellular
receptors, translocation to the nucleus and transcription
of androgen related genes, as the prostate specific antigen
(PSA). In recent years, however, evidences have been accu-
mulated that steroid, including androgen, action can also
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be mediated by non-classical, membrane receptor sites.
These latter are biochemically distinguishable from intra-
cellular androgen receptors, and their activation results in
rapid non-genomic effects [1–5], elicited minutes after
binding. Classical and non-classical binding sites can co-
exist in the same cells [1,2].
Recently we have reported the identification of a function-
al membrane testosterone binding site on LNCaP prostate
cancer cell line [6]. Its activation results in the rapid (with-
in minutes) secretion of stored PSA, through a specific sig-
naling cascade (Papakonstanti et al, submitted) leading to
actin cytoskeleton rearrangements. The identification of
this membrane testosterone binding site is a constant
characteristic of androgen receptor positive and negative
cell lines, independently of the expression of intracellular
receptors (Kogia et al in preparation). In the present work,
we investigated whether membrane testosterone sites are
expressed in human prostate carcinomas. In addition, we
have investigated whether these sites are differentially ex-
pressed in malignant and non-malignant (benigh prostate
hyperplasia and non-malignant prostate cells) prostate
epithelial cells, using a number of methods. We show that
membrane testosterone binding sites are preferentially ex-
pressed in carcinomas, and therefore they could provide
additional evidences for the diagnostic discrimination of
prostate cancer.
Methods
Tissues examined
Prostate carcinoma tissue was obtained from fourteen
(14) fresh radical prostatectomy specimens. Carcinomas
were diagnosed preoperatively by needle biopsy under
transurethral ultrasound guidance, and verified and grad-
ed according to Gleason grading system [7–9], on forma-
lin fixed-paraffin embedded sections of the surgical
specimens (Table 1). All patients were free from preoper-
ative chemotherapy, irradiation, or hormonal therapy. Re-
gional lymph nodes (examined during the operation on
rapid frozen sections) were free of metastases. Other me-
tastases were not detected on extensive preoperative study.
Microscopically non-malignant epithelia from the radical
prostatectomy specimens were also harvested (n = 8). Ad-
ditionally, fresh tissue samples were obtained from ten
(10) patients treated by transurethral resection for benign
prostate hyperplasia. In two of the benign prostate hyper-
plasia cases, high-grade prostate intraepithelial neoplasia
foci were found and examined.
Tissue dissociation and cell suspension preparation
The surgical specimens were rinsed by normal saline, in
the operation theater, placed immediately after their exci-
sion in cold (4°C) phosphate buffered saline (PBS) pH
7.4 and immediately transferred to the Surgical Pathology
Laboratory, where they were processed in no more than
20 minutes. Touching preparations were made on Super-
Frost Plus slides (Kindler O GmbH, Freiburg, Germany),
stained with Hematoxylin-Eosin (HE) and examined mi-
croscopically to ensure tumor location, and hence the rep-
resentative sampling of the carcinomatous and non-
carcinomatous tissue, or processed for membrane andro-
gen binding sites staining, as described below. Tissue
chips from transurethral specimens were picked up in a
random way and processed as described above.
Cell suspensions were prepared in cold (4°C) RPMI 1640
culture medium (GIBCO BRL/Life Technologies, Paisley,
U.K). Each tissue sample was placed in a Petri dish with 4
ml RPMI 1640 medium, minced thoroughly with a scalpel
until fragments were less than 1 mm in diameter, then re-
peatedly pipetted with a Pasteur pipette in order to loosen
the fragmented tissue into a single cell suspension, and
poured to a 10 ml glass tube through a sterile multilayer
cotton gauze pad to remove clumps and debris. Cell sus-
pension was washed twice with cold medium, and resus-
pended in 1 ml RPMI 1640.
In order to identify the cells yield by the above described
technique, cells were stained with antibodies to vimentin
(clone V6, code #M 0725, dilution 1/20), human cytok-
eratine (clone MNF 116, code #M 0821, dilution 1/25)
and PSA (polyclonal antibody code #A 0562, dilution 1/
100), all purchased from DAKO, Glostrup, Denmark. Cell
preparations were applied on SuperFrost Plus slides (Kin-
dler O GmbH, Freiburg, Germany), then smeared on the
slides, immediately fixed for 30 minutes in 1/1 cold ace-
tone-methanol (v/v), stained using the alkaline phos-
phatase-antialkaline phosphatase (APAAP) method [10],
and examined with a Microphot-FXA microscope, mount-
ed with a Nikon DX-DB2 photographic camera.
Preparation of formalin-fixed paraffin-embedded tissue 
sections for the detection of membrane androgen binding 
sites
Tissue sections were prepared from paraffin blocks of for-
malin fixed tissues. Three microns (µm) thick tissue sec-
tions were cut and layered on SuperFrost Plus slides
(Kindler O GmbH, Freiburg, Germany), incubated at
56°C for 2 h, washed six times with xylene (5 min each),
followed by 96%, 80% and 70% ethanol (five minutes
each), and finally with distilled water for 20 min. Tissue
slides were then incubated in citrate buffer in a micro-
waves oven at 500 Watts, three times for 4.5 minutes each,
washed in distilled water and Tris buffered saline (TBS, 10
mM, NaCl 150 mM, pH 7.4). Non-specific absorption of
BSA was minimized by 10 min preincubation of the slides
with a 2% solution of BSA in TBS, followed by two washes
with TBS.BMC Clinical Pathology 2003, 3 http://www.biomedcentral.com/1472-6890/3/1
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Detection of membrane androgen binding sites
Flow cytometry
Cell suspensions were incubated at room temperature
with 10-7  M testosterone-BSA-FITC conjugate, as de-
scribed previously [6]. A thousand-fold BSA-FITC was
used, to determine non-specific binding. Cells were ana-
lyzed by flow cytometry using a Coulter Epics XL-MCL ap-
paratus (Beckman-Coulter Inc. Foullerton CA, USA) in a
sample size of 10,000 cells, gated on the basis of forward
and side scatter, as previously described [6].
Testosterone3-(O-carboxymethyl)oxime-BSA-FITC, and
BSA-FITC, were obtained from Sigma (St Louis, MO).
Confocal Microscopy
Cell suspensions were placed on SuperFrost Plus slides,
preincubated for 10 min with a 2% solution of BSA in
TBS, were washed twice with TBS and incubated with Tes-
tosterone-BSA-FITC (10-6 M) for 30 min. As a negative
control the same concentration (10-6 M) BSA-FITC was
used. Cells were then fixed with 2% PFA in PBS for 30
min. Coverslips were mounted on to slides using a 1:1 (v/
v) mixture of glycerol and (Vector, Burlingame, CA). For
Vectashield  the detection of membrane androgen
binding sites on tissue sections, processed as described
above, a 10-min incubation with testosterone-BSA-FITC
was made, followed by a washing in TBS. Testosterone-
BSA-FITC binding was analysed using a confocal laser
scanning microscope (CLSM) (Leica TCS-NT).
Table 1: Summary of cases examined in the present study. Cases 9 and 10 marked with with asterisks represent cases of PIN.
Kind of surgery Specimen No Prostate cancer Gleason Score Hyperplasia Specific testosterone 
Binding (log scale)
Radical 1 + (4+4) 8 - 0,6532
Prostatectomy 2 + (4+4) 8 - 0,5772
" 7 + (4+3) 7 - 0,7112
" 11 -+ 0,359
" 13 -+ 0,176
" 14 + (3+4) 7 - 0,77
" 15 + (3+4) 7 - 0,014
" 20 + (3+5) 8 - 0,439
" 35 + (3+4) 7 - 0,6
" 36 + (3+4) 7 - 0,74
" 38 + (3+4) 7 - 0,57
" 40 + (3+3) 6 - 0,5698
" 9* -+ 0,5314
" 10* -+ 0,447
Transurethral Resection 3 -+ 0,397
4 -+ 0,39
" 5 -+ 0,221
" 6 +- 0,509
" 16 + (3+2) 5 - 0,67
" 17 -+ 0,096
" 18 -+ 0,23
" 19 -+ 0,143
" 29 -- 0,12
" 30 -- 0,02
" 33 -+ 0,079
" 34 -+ 0,3
Radical Prostatectomy 
(non-malignant)
8 -- 0,398
- 12 -- 0,038
- 21 -- 0,166
" 22 -- 0,259
" 32 -- 0,034
" 37 -- 0,52
" 39 -- 0,268
" 41 -- 0,367BMC Clinical Pathology 2003, 3 http://www.biomedcentral.com/1472-6890/3/1
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Figure 1
Detection of membrane Testosterone receptors in prostat epithelial cells by flow cytometry. A: Cells were iso-
lated from specimens of radical prostatectomy, as described in Material and Methods, stained for 10 min with 10-7 M of testo-
sterone-BSA-FITC (blue curve, 2) or BSA-FITC (yellow curve, 1), and the fluorescence was measured in a Coulter-Epics 
apparatus. The specific fluorescence is the difference of the two peaks (bar B). B: Time course of the specific testosterone-
BSA-FITC fluorescence (bar A in Figure 1A). Results of a typical experiment (case number 35 in Table 1).BMC Clinical Pathology 2003, 3 http://www.biomedcentral.com/1472-6890/3/1
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Results
Mechanical dissociation of cells from selected regions of
prostate specimens yielded mainly epithelial cells, as re-
vealed by cytokeratin and PSA staining. We prefered this
mild dissociation method, as enzymatic treatment of tis-
sue specimens could modify membrane structures, lead-
ing to a loss of membrane testosterone binding. By
touching preparations we ensured about the quality (not
necrotic tissue, representative sample) of the tissue speci-
mens obtained, while by immunostaining we ensured
that the dissociation of tissues yielded epithelial cells, and
the suspensions contained only malignant or non-malig-
nant cells, as per case. Epithelial cells accounted for more
than 85% of total cells, in all studied specimens. On con-
focal microscopy and flow cytometry, only carcinoma
cells exhibited detectable reactivity with testosterone-BSA-
FITC. A typical result is presented in Figure 1. As shown, a
85% maximal specific staining with testosterone-BSA-
FITC was found, compatible with the percentage of epi-
thelial cells in our preparations.
In Figure 2, typical cases of testosterone-BSA-FITC binding
on cells prepared from prostate carcinoma (left panel)
and benign prostate hyperplasia (right panel) are present-
ed. As shown, Testosterone-BSA-FITC binds only to malig-
nant cells, showing a peripheral annular staining.
Although some unavoidable, slight, background reaction
is evident with different intensity in both panels, no cell
staining can be seen on the right one (BPH case). In addi-
tion, non-malignant cells, isolated from prostatectomy
specimens, do not show any membrane testosterone
binding. As in the case of LNCaP cells, the identification
of membrane testosterone receptors can be obtained in
short incubation times. It is evident after one minute in-
cubation, and maximum binding is observed after 15 min
(Fig. 1). Thereafter, fluorescence intensity remains con-
stant for times up to one hour. As reported before for
LNCaP cells [6], no internalization of the tracer was ob-
served in any case of malignant or non-malignant cells,
confirming that testosterone-BSA analog binds exclusively
to membrane testosterone sites. Although the selectivity
of the binding was not assayed in the present study, our
previous results [6] indicate that this site is selective for
androgens.
Figure 2
Detection of membrane androgen binding sites in cells isolated from benign (right panel) and malignant (left 
panel) prostate lesions examined by Confocal microscopy. Positive staining can be seen only on the preparation of car-
cinoma cells. No staining is evident on the right panel corresponding to preparation of BPH epithelial cells.                BMC Clinical Pathology 2003, 3 http://www.biomedcentral.com/1472-6890/3/1
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Figure 3 depicts the flow cytometry analysis of membrane
testosterone binding in cases of malignant and non-ma-
lignant cells isolated from surgical specimens of the pros-
tate. Due probably to the higher discrimination potency
of the method, a specific testosterone-BSA binding was re-
vealed in all cells. The intensity of testosterone-BSA-FITC
staining was different depending on the nature of cells ex-
amined: for normal cells and benign prostate hyperplasia
the staining was very low, while cells from prostate cancer
were intensively stained. Quantification of flow cytometry
results showed that testosterone-BSA-FITC binding was
significantly higher in prostate carcinomas as compared to
BPH (t = 7.65, p < 0.001) and normal tissue (t = 7.65, p <
0.001). These two latter groups showed similar results
(Table 1).
In order to be useful in everyday practice, the detection of
membrane testosterone binding sites should be per-
formed on routine histology slides. In this aim, we have
developed a method for the identification of the testoster-
one membrane binding sites on formalin-fixed, paraffin-
embedded routine prostate tissue sections, as described in
Material and Methods. Applying this protocol, membrane
testosterone binding sites could be identified in tissue sec-
tions obtained from the same cases studied by flow cy-
tometry. As shown in Figure 4, carcinoma cells and cells of
PIN fixed the testosterone tracer intensely and consistent-
ly, and the pattern of reaction was peripheral and annular.
In addition, due to the very fine thickness of slices (2 µm),
a nuclear staining is also obtained, making the method
also useful for the detection of classical androgen recep-
tors, in addition of membrane receptors. A slight mem-
Figure 3
Distribution of testosterone-BSA-FITC specific fluorescence intensity in cells isolated from prostate carcino-
mas or benign prostate hyperplasia, and morphologically normal prostate epithelial cells, detected by flow 
cytometry. Fluorescent intensity was calculated as the peak fluorescence difference in cells stained with testosterone-BSA-
FITC and BSA-FITC. Bars indicate the mean value. ***: p < 0.001 at least. Results are presented on a logarithmic scale.BMC Clinical Pathology 2003, 3 http://www.biomedcentral.com/1472-6890/3/1
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brane staining was also observed in some cases of BPH
and in some normal epithelia of the gland (not shown).
In some cases, in spite of a preincubation with BSA, stro-
mal structures could fix low amounts of tracer, which in
no way interfere with the epithelial structure staining esti-
mation, and do not restrict the efficiency of the method.
Discussion
Prostate carcinoma is, at least initially, a hormone-regulat-
ed neoplasm, but under therapy eventually escapes and
relapses [2,11–17]. Androgen effects are classically exerted
through binding of the hormone to intracellular specific
receptors [18,19], which consequently dimerize, translo-
cate to the nucleus and bind to specific elements of DNA,
affecting thus the transcription of androgen-responsive
genes [14]. In recent years, evidence has been accumulat-
ed, indicating that androgen can alternatively exert on re-
spective target cells short-time non-genomic effects
mediated through membrane binding sites and subse-
quent changing in Ca2+ concentration [4,5,20,21], in cell
types presenting [1,2] or lacking intracellular androgen re-
ceptors [3–5]. Quite recently we have described a mem-
brane testosterone binding site in the hormone positive
human prostate cancer cell line LNCaP [6]. We have
shown that activation of this site initiates within minutes
the rearrangement of actin cytoskeleton through a specific
signaling cascade (Papakonstanti et al, submitted) and
increases the secretion of PSA. This site was selective for
androgens, and immunologically different from the intra-
cellular classical testosterone receptor. In addition, no in-
ternalization of membrane testosterone sites was obvious
after incubation times less than one hour.
The results of the present study indicate that membrane
testosterone binding sites can also be identified in  freshly
prepared human prostate cells. This binding was re-
strained to epithelial cells and is completed within min-
utes (Figure 1). Neoplastic cells, morphologically normal
prostate epithelium cells and BPH epithelia bind testo-
sterone-BSA analog (Figure 3, Table 1) but with a different
intensity. In this respect, as presented in Figure 3, a clear
discrimination of malignant and non-malignant cells
could be obtained by membrane testosterone binding.
This is also evident in touching preparations (Figure 2)
and histological preparations of prostate cancer (Figure
4). It is of interest to note that cells underwent prostate in-
traepithelial neoplasia (PIN) are also intensely stained
with testosterone-BSA, indicating that the expression of
these sites might correlate with a neoplastic and premalig-
nant (PIN) phenotype. With more sensitive methods
however (flow cytometry), some slight staining-reaction
of normal and BPH epithelia was also evidenced. In this
Figure 4
Detection of membrane testosterone binding sites in prostate cancer. Left panel depicts three micron sections, 
stained with hematoxylin-eosin. The boxed section is shown in the right panel, stained by testosterone-BSA-FITC (10-6 M) and 
examined in a confocal microscope. A median confocal section is presented.                BMC Clinical Pathology 2003, 3 http://www.biomedcentral.com/1472-6890/3/1
Page 8 of 9
(page number not for citation purposes)
respect, the difference between neoplastic and non-neo-
plastic cells is merely a quantitative differential expres-
sion. Indeed, two cases of transurethral resection (Table 1)
in which high testosterone-BSA-FITC staining was ob-
tained, were revealed to present foci of PIN after a thor-
ough histological examination.
Traditionally the differential diagnosis, grading and stag-
ing of prostate carcinoma has been based predominantly
on morphological features [9,22,23]. A number of immu-
nological markers have been proposed in prostate carci-
noma or premalignant conditions (such as PIN), but they
lack selectivity and specificity [9,22–29]. Indeed, a good
biomarker can be defined as one that adds independent
information to standard prognostic indicators, and which
can be reliably reproduced in the laboratory, aiding in di-
agnostic and/or therapeutic decisions. Our results indicate
that membrane testosterone binding sites could fulfill this
definition, as they can aid in discrimination between be-
nign and malignant/premalignant prostate conditions. As
shown in Figure 3, in only one case of morphologically
normal epithelial cells the values overlapped with those
obtained in the carcinoma group. It is possible, however,
that a number of tumor cells could interfere with the
measurement. In addition, two samples, initially consid-
ered as BPH, but finally diagnosed as harboring PIN le-
sions were positively stained for membrane testosterone
binding sites, indicating the potential diagnostic useful-
ness of membrane testosterone binding sites identifica-
tion and/or measurement. Although further
investigations in large series are needed, our results indi-
cate that membrane testosterone binding sites could be a
valuable addition in prostate cancer differential diagnosis,
and a possible target for novel therapies.
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